SCHEMBL19971599

SCHEMBL19971599

COC(=O)c1cc(F)cc(Br)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.49
SLC6A3 Q01959 2/20 0.40
SLC6A4 P31645 1/20 0.40
NOTUM Q6P988 2/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
PDK2 Q15119 1/20 0.38
PDK4 Q16654 1/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NR4A2 P43354 1/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31055681 1.00 SOS1 (0.49) SOS1SLC6A3SLC6A4NOTUMCES2
SCHEMBL5853128 0.85 SOS1 (0.49) SOS1SLC6A3SLC6A4NOTUMCA12
SCHEMBL30296704 0.84 SOS1 (0.44) SOS1SLC6A3SLC6A4NOTUMCA12
SCHEMBL21817258 0.84 SOS1 (0.48) SOS1NOTUMCA12CA1CA2
SCHEMBL31283849 0.84 SOS1 (0.44) SOS1SLC6A3SLC6A4NOTUMCA12
SCHEMBL25308574 0.84 CA12 (0.49) SOS1NOTUMCA12CA1CA2
SCHEMBL16048883 0.84 SOS1 (0.44) SOS1SLC6A3SLC6A4NOTUMCA12
SCHEMBL3413587 0.84 SOS1 (0.44) SOS1SLC6A3SLC6A4NOTUMCA12
SCHEMBL16069727 0.84 SOS1 (0.48) SOS1NOTUMCA1CA2ALDH1A1
SCHEMBL31502301 0.83 SOS1 (0.54) SOS1SLC6A3SLC6A4NOTUMCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 US disclosed
EP-4448522-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-10-23 EP disclosed
CN-118488953-A Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors 豪夫迈·罗氏有限公司 2024-08-13 CN disclosed
WO-2023110958-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-06-22 WO disclosed
WO-2018057219-A1 METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES SPECTRUM TRACER SERVICES, LLC (US) 2018-03-29 WO disclosed
US-20180080314-A1 METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES SPECTRUM TRACER SERVICES, LLC 2018-03-22 US disclosed
CN-104395297-B Sulfonamide derivatives and pharmaceutical use thereof AJINOMOTO CO.,INC. (JP) 2016-05-04 CN disclosed
CN-102015674-B Modulators of dopamine neurotransmission NSAB FILIAL AF NEUROSEARCH SWEDEN AB SVERIGE (DK) 2014-10-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS MGLL, LIPC, PNLIP SOS1 4362/4885SLC6A3 4707/4885SLC6A4 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.